Talquetamab Well Tolerated in Relapsed/Refractory MM

from Oncology Learning Network · host HMP Global

Jesus Berdeja, MD, shares findings from a phase 1 study of talquetamab therapy for relapsed/refractory MM. These data are being presented at the 2021 ASCO Annual Meeting.

Episode metadata supplied by the publisher feed · Published Jun 8, 2021

Embed this episode

Attribution link and audio player

Ready to play

Talquetamab Well Tolerated in Relapsed/Refractory MM

0:00 4:24

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 4 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on June 8, 2021.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!